Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Open-label, Single-arm, Multi-center Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly

Next Previous
Trial Profile

A Phase 3, Open-label, Single-arm, Multi-center Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Octreotide (Primary)
  • Indications Acromegaly
  • Focus Adverse reactions; Registrational
  • Acronyms ACROINNOVA 2
  • Sponsors Camurus

    • Most Recent Events

    • 21 Dec 2023 According to a Camurus media release, company announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Oclaiz (CAM2029), the companys investigational, once-monthly octreotide subcutaneous (SC) depot for the treatment of patients with acromegaly. The NDA submission follows recent announcements of positive results from the two Phase 3 ACROINNOVA studies and completed pre-NDA meetings with the US FDA.
    • 17 Jul 2023 According to a Camurus media release, data from this study will be presented the upcoming medical meetings and in a scientific publication.
    • 17 Jul 2023 According to a Camurus media release, the interim data from this study will be a part of the regulatory submissions for CAM2029.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top